{
    "medicine_id": "4263e38579261d126a533042b1bd4b7831f9e1ee",
    "platform_id": "DB13161",
    "metadata": {
        "name": "Spinraza 2 4 mg 1mL Injection solution",
        "composition": "2 4 mg 1mL Nusinersen",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for the treatment of spinal muscular atrophy SMA in pediatric and adult patients",
            "contraindications": {
                "disease": "Single injection to adult monkeys produced apparent acute neurological impairment",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Autopsy samples from patients n 3 had higher levels of SMN2 messenger ribonucleic acid mRNA containing exon 7 in the thoracic spinal cord compared to untreated SMA infants Cardiac Electrophysiology In 121 patients with spinal muscular atrophy who received either nusinersen or sham control QTcF values 500 ms and change from baseline values 60 ms were observed in 5 of patients receiving nusinersen Compared to the sham control there was no increase in the incidence of cardiac adverse reactions associated with delayed ventricular repolarization in patients treated with nusinersen",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}